Health and Healthcare

Biotech Implosion: CombinatoRx (CRXX)

CombinatoRx, Incorporated (NASDAQ: CRXX) is seeing its stock implode this morning.  The company released data from its Phase IIb study of Synavive (CRx-102) for knee osteoarthritis showing that its Synavive test was not statistically significant.  This is likely more than just a setback for the Synavive program, but CombinatoRx said it will continue to evaluate and analyze the data. 

Shareholders and traders alike are firing first and asking questions later.  Shares closed at $3.00 Friday and its 52-week trading range was $2.86 to $6.99. Its pre-market stock trading indications are down nearly 60% at $1.25.

Jon C. Ogg
October 6, 2008

Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)

Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.

Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.

Click here now to get started.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.